Merck publish series of T-Type Calcium Channel blockers

Merck have published a series of  T-Type Calcium Channel blockers

FDA approves Exforge and Diovan HCT

The US FDA has approved Diovan HCT (valsartan/hydrochlorothiazide) and Exforge (amlodipine/ valsartan), as first-line therapies in patients who need multiple drugs to achieve their blood pressure goals.

Ore acquire tiapamil from Roche

Ore Pharmaceuticals have acquired Ca channel antagonist tiapamil from Roche. The company plan to develop the drug for CNS indications

Cleviprex approved in US

The FDA has approved The Medicines Company’s ca channel blocker Cleviprex for the IV treatment of hypertension

Resiniferatoxin inhibits Ca2+ channels independent of TRPV1

Researchers from Brigham & Women’s Hospital have shown that resiniferatoxin blocks voltage-dependent Ca2+ channels independently of TRPV1

Cleviprex controls perioperative hypertension, may reduce heart attack

Data presented at the SCA Meeting show The Medicine Company’s Calcium channel antagonist Cleviprex injectable may reduce the risk of heart attack compared to two other antihypertensive agents.

Merck publish series of novel T-type Ca channel antagonists

Merck have published a series of novel T-type Ca channel antagonists. Compounds displayed in vivo CNS efficacy without adverse cardiovascular effects

Newron completes Phase III recruitment for Safinamide in Parkinsons

Newron completes Phase III recruitment for Safinamide in Parkinsons

YM-758 pharmacokinetics in rats and humans

The hepatic uptake and excretion of YM-758 is otlined in a Drug Metabolism and Disposition paper. YM-758 was discontinued in Dec 2007 due to an unsatisfactory safety profile

Azor shows efficacy in difficult to treat patient groups

Data presented at ASH shows that Azor (amlodipine and olmesartan medoxomil) safely and effectively lowered blood pressure, especially in several key difficult to treat patient groups such as in those of African and Hispanic/Latino decent